Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05834738 · ClinicalTrials.gov registry record · Phase 2
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT05834738 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 54 participants.
The verdict
NCT05834738, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
The ASSIST study is a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).
Interventions
- DRUG Placebo
- DRUG Atrasentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2023-07-20 |
| Est. Completion | 2025-10-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05834738
The ClinicalTrials.gov registry entry for NCT05834738 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05834738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05834738 about?
NCT05834738 is a clinical study titled "Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy". The ASSIST study is a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).
What is the current status of trial NCT05834738?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2023-07-20. Estimated completion is 2025-10-29.
What interventions are being tested in trial NCT05834738?
The interventions under investigation include: Placebo (DRUG), Atrasentan (DRUG).
Who is sponsoring clinical trial NCT05834738?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.